Jens Würthner, MD PhD, is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a fellow of the Faculty of Pharmaceutical Medicine, UK and visiting senior lecturer for Kings College, School of Biomedical Sciences, in London.
Dr. Würthner qualified as a physician in Hamburg, Germany, and entered clinical oncology at the University of Freiburg, followed by cancer research at the National Institutes of Health, Bethesda, USA. During the latter he identified a novel class of proteins, which he demonstrated to be essential components of the TGF-beta signaling cascade.
After joining the pharmaceutical industry, Dr. Würthner worked in early clinical development for AstraZeneca, GlaxoSmithKline and Novartis across oncology, infection and immunology. His most significant contributions to the field were in translational and early clinical development of Olaparib in ovarian cancer, of Cytofab and GSK1995057 in sepsis and acute lung injury, respectively, and of CGM097 and HDM201, two MDM2 inhibitors, across several solid and hematological tumor indications.